Moderna's stock dropped 4% following an earlier 18% plunge after the release of positive late-stage results for its personalized melanoma vaccine co-developed with Merck. Although the vaccine showed a reduction in melanoma recurrence risk, the results fell short of the highest market expectations, prompting a selloff concentrated in Moderna shares. Merck and Pfizer shares dipped slightly but remained relatively stable due to their broader product bases. The upcoming full presentation at a medical conference may influence further market reactions.
Moderna shares are down 6.86% on Pluang as of Oct 23, 2026 20:32 WIB, trading at USD 188.73 with a market cap of $80.90B. This decline aligns with the article's note of a 4% drop following the melanoma vaccine news. Merck and Pfizer also show modest declines on Pluang, with Merck down 1.68% at USD 144.77 and Pfizer down 0.62% at USD 30.23, reflecting cautious market sentiment in the health sector.
Moderna's shares fell nearly 18% after positive Phase 3 results for its personalized melanoma vaccine with Merck were leaked early, causing market uncertainty despite the promising data. Meanwhile, SpaceX is negotiating with major infrastructure firm...
Moderna's stock dropped sharply by over 21% in two days following the leak of early Phase 3 trial results for its personalized cancer vaccine and a major downgrade from Citi, which issued a 'Sell' rating and an $80 price target. Despite the leaked re...
Moderna's stock fell up to 25% following the leak of partial data on its cancer vaccine developed with Merck, despite the full phase 3 trial results later showing positive outcomes. The vaccine, combined with Merck's Keytruda, reduced the risk of mel...
Moderna's stock fell sharply by 25% following an unauthorized leak of Phase 3 data for its experimental cancer vaccine developed with Merck. The data was expected to be officially presented at a medical conference this weekend. Merck's shares also de...
Moderna's stock dropped 25% after a late-stage melanoma vaccine report was briefly posted online and then removed. The vaccine, developed with Merck, showed favorable results in reducing melanoma recurrence or death when combined with Keytruda, but t...
